Tudor Investment Corp ET AL cut its position in shares of FibroGen, Inc (NASDAQ:FGEN) by 35.7% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,296 shares of the biopharmaceutical company’s stock after selling 6,279 shares during the period. Tudor Investment Corp ET AL’s holdings in FibroGen were worth $278,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently made changes to their positions in FGEN. BlackRock Inc. raised its position in shares of FibroGen by 29,724.1% in the first quarter. BlackRock Inc. now owns 4,454,819 shares of the biopharmaceutical company’s stock worth $109,811,000 after buying an additional 4,439,882 shares during the last quarter. FMR LLC raised its stake in FibroGen by 72.5% in the fourth quarter. FMR LLC now owns 1,533,431 shares of the biopharmaceutical company’s stock valued at $32,815,000 after buying an additional 644,528 shares in the last quarter. Norges Bank purchased a new stake in FibroGen during the fourth quarter valued at about $8,480,000. Vanguard Group Inc. raised its stake in FibroGen by 8.4% in the first quarter. Vanguard Group Inc. now owns 5,047,018 shares of the biopharmaceutical company’s stock valued at $124,409,000 after buying an additional 392,778 shares in the last quarter. Finally, Bogle Investment Management L P DE raised its stake in FibroGen by 215.8% in the first quarter. Bogle Investment Management L P DE now owns 329,371 shares of the biopharmaceutical company’s stock valued at $8,118,000 after buying an additional 225,083 shares in the last quarter. Institutional investors and hedge funds own 43.45% of the company’s stock.
Shares of FibroGen, Inc (NASDAQ:FGEN) opened at 41.65 on Friday. FibroGen, Inc has a 52-week low of $15.60 and a 52-week high of $51.70. The stock’s 50 day moving average is $34.92 and its 200 day moving average is $28.29. The firm’s market capitalization is $2.97 billion.
FibroGen (NASDAQ:FGEN) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.01. FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The firm had revenue of $29 million for the quarter, compared to the consensus estimate of $34.80 million. On average, equities research analysts forecast that FibroGen, Inc will post ($1.82) EPS for the current year.
TRADEMARK VIOLATION WARNING: This story was published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://www.com-unik.info/2017/08/12/tudor-investment-corp-et-al-has-278000-stake-in-fibrogen-inc-nasdaqfgen-updated-updated.html.
Several research firms recently issued reports on FGEN. William Blair reiterated an “outperform” rating on shares of FibroGen in a research report on Wednesday. Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research note on Friday, July 21st. BidaskClub downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Leerink Swann reissued an “outperform” rating and issued a $82.00 price objective (up previously from $52.00) on shares of FibroGen in a research note on Tuesday. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $75.00 price target on shares of FibroGen in a research note on Tuesday. One analyst has rated the stock with a sell rating, one has given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The company has an average rating of “Buy” and an average target price of $60.17.
In related news, Director Toshinari Tamura sold 30,000 shares of the company’s stock in a transaction on Monday, June 12th. The shares were sold at an average price of $28.89, for a total transaction of $866,700.00. Following the completion of the sale, the director now directly owns 60,000 shares in the company, valued at approximately $1,733,400. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Pat Cotroneo sold 95,000 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $50.61, for a total transaction of $4,807,950.00. Following the sale, the vice president now owns 173,366 shares of the company’s stock, valued at $8,774,053.26. The disclosure for this sale can be found here. Insiders have sold a total of 537,474 shares of company stock valued at $19,220,138 over the last quarter. 14.90% of the stock is currently owned by company insiders.
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
What are top analysts saying about FibroGen Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for FibroGen Inc and related companies.